Stress in women: Metabolic syndrome and polycystic ovary syndrome

Annals of the New York Academy of Sciences

Volumn 1083, Issue , 2006, Pages 54-62

  Diamanti Kandarakis, Evanthia ^a   Economou, Frangiskos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Metabolic syndrome; Polycystic ovary syndrome; Stress

Indexed keywords

ADULTHOOD; ANOVULATION; ATHEROGENESIS; ATHEROSCLEROSIS; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERINSULINISM; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PRENATAL PERIOD; SMOKING CESSATION; STRESS; SYMPTOMATOLOGY; THROMBOSIS;

EID: 33845626022     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1367.006     Document Type: Conference Paper

References (55)

1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004 19: 41-47.
2. STEIN, I.F. & M. LEVENTHAL. 1935. Amenorrhoea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29: 181-191.
3. DIAMANTI-KANDARAKIS, E. et al. 1999. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84: 4006-4011.
4. ASUNCION, M. et al. 2000. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85: 2434-2438.
5. AZZIZ, R. et al. 2004. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89: 2745-2749.
6. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. 2002. Circulation 106: 3143-3421.
7. SAM, S. et al. 2003. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol. Metab. 14: 365-370.
8. DUNAIF, A. 1997. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18: 774-800.
9. CHANG, R.J. et al. 1983. Insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 57: 356-359.
10. DUNAIF, A. et al. 1989. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165-1174.
11. BOOK, C.B. et al. 1999. Selective insulin resistance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 84: 3110-3116.
12. DUNAIF, A. et al. 1995. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. J. Clin. Invest. 96: 801-810.
13. DUNAIF, A. et al. 2001. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am. J. Physiol. Endocrinol. Metab. 281: E392-E399.
14. LEGRO, R.S. et al. 1999. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84: 165-169.
15. EHRMANN, D.A. et al. 1999. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141-146.
16. DAHLGREN, E. et al. 1992. Women with polycystic ovary syndrome wedge resected in 1956-65: a long-term follow-up focusing on natural history and circulating hormones. Fertil. Steril. 57: 505-513.
17. TALBOTT, E.O. et al. 2004. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol. 56: 27-39.
18. DAHLGREN, E. et al. 1994. Polycystic ovary syndrome long-term metabolic consequences. Int. J. Gynecol. Obstet. 44: 3-8.
19. CIBULA, D. et al. 2000. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary heart disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum. Reprod. 15: 785-789.
20. WILD, R.A. et al. 1985. Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 61: 946-951.
21. TALBOTT, E.O. et al. 1998. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case control study. J. Clin. Epidemiol. 51: 415-422.
22. MATHER, K.J. et al. 2000. Hyperinsulinemia in polycystic ovary syndrome correlated with increased cardiovascular risk independent of obesity. Fertil. Steril. 73: 150-156.
23. LEGRO, R.S. et al. 2001. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111: 607-613.
24. DEJAGER, S. et al. 2001. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin. Endocrinol. 54: 455-462.
25. PIRWANY, I.R. et al. 2001. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin. Endocrinol. 54: 447-453.
26. SAMPSON, M. et al. 1996. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin. Endocrinol. 45: 623-629.
27. EHRMANN, D.A. et al. 1997. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82: 2108-2116.
28. EVANTHIA DIAMANTI-KANDARAKIS, et al. 2004. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur. J. Endocrinol. 150: 793-798.
29. KELLY, C.C.J. et al. 2001. Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 86: 2453-2455.
30. BOULMAN, N. et al. 2004. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J. Clin. Endocrinol. Metab. 89: 2160-2164.
31. BAHCECI, M. et al. 2004. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm. Res. 62: 283-287.
32. SJOHOLM, E. et al. 2005. Endothelial inflammation in insulin resistance. Lancet 365: 610-612.
33. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS. 2004. Position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocri. Pract. 11: 126-134.
34. GONZALEZ, F. et al. 1999. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary. Syndr. Metab.. 48: 437-441.
35. PARADISI, G. et al. 2001. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103: 1410-1415.
36. DIAMANTI-KANDARAKIS, E. et al. 2001. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab. 86: 4666-4673.
37. DAHLGREN, E. et al. 1992. Women with polycystic ovary syndrome wedge resected in 1956 to 1965 : a long-term follow-up focusing on natural history and circulating hormones. Fertil. Steril. 57: 505-513.
38. ELTING, M.W. et al. 2001. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum. Reprod. 16: 556-560.
39. VRBIKOVA, J. et al. 2003. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum. Reprod. 18: 980-984.
40. ENGELI, S. et al. 2003. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 35: 807-825.
41. GAMBINERI, A. et al. 2002 Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord.. 26: 883-896.
42. CARMINA, E. et al. 2003. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod. 18: 2289-2293.
43. GLUECK, C.J. et al. 2003. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52: 908-915.
44. APRIDONIDZE, T. et al. 2004. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.. First published December 28, as doi:10.1210/jc.2004-1045.
45. ROSMOND, R. 2005. Role of stress in the pathogenesis of metabolic syndrome. Psychoneuroendocrinology 30: 1-10.
46. PHILLIPS, D.I. 2004. Fetal programming of the neuroendocrine response to stress: links between low birth weight and the metabolic syndrome. Endocr. Res. 30: 819-826.
47. ONG, K. 2005. Adrenal function of low-birthweight children. Endocr. Dev. 8: 34-53.
48. IBANEZ, L. et al. 1999. Anovulation after precocious pubarche: early markers and time course in adolescence. J. Clin. Endocrinol. Metab. 84: 2691-2695.
49. IBANEZ, L. et al. 1993. Post-pubertal outcome in girls diagnosed of premature pubarche during childhood: increased incidence of functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 76: 1599-1603.
50. IBANEZ, L. et al. 1998. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism risk in girls: relation to reduced fetal growth. J. Clin. Endocrinol. Metab. 83: 3558-3662.
51. IBANEZ, L. et al. 2000. Premature adrenarche: normal variant or forerunner of adult disease. Endocr. Rev. 21: 671-696.
52. CHEKIR, C. et al. 2005. Impaired uterine perfusion associated with metabolic disorders in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 84: 189-195.
53. LARA, H.E. et al. 2002. Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: studies on norepinephrine release. Microsc. Res. Tech. 59: 495-502.
54. COFFEY, S. et al. 2003. The effect of polycystic ovary syndrome on health-related quality of life. Gynecol. Endocrinol. 17: 379-386.
55. DIAMANTI-KANDARAKIS, E. & A. KANDARAKIS. 2004. Obesity and gonadal function of women. Pediatr. Endocrinol. Rev. No. 1. S3: 465-470.